News
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
Alzheimer's patients could soon have more treatment options available. Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
Alzheimer's patients could soon have more treatment options available. Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli
Pfizer's Profits Plunge 77%: Is the Dividend Still Safe?
Pfizer (NYSE: PFE) provides investors with an attractive dividend that currently yields 4.7%. To collect $1,000 in annual dividends at that rate, you would need to invest approximately $21,300
Pfizer's Profits Plunge 77%: Is the Dividend Still Safe?
Pfizer (NYSE: PFE) provides investors with an attractive dividend that currently yields 4.7%. To collect $1,000 in annual dividends at that rate, you would need to invest approximately $21,300
Is Viatris Stock Good for Dividend Income?
Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines
Is Viatris Stock Good for Dividend Income?
Viatris (NASDAQ: VTRS) is a stock of immense interest among the dividend investing community, and it's no surprise why. Generic drugmakers, when operating smoothly, can be veritable cash machines
Investing $1,000 in These 2 Top Stocks Would Be a Brilliant Move
One of the great things about investing in stocks is that there is no need to have millions in the bank to get started. A relatively modest sum such as $1,000 can go a long way if invested shrewdly
Investing $1,000 in These 2 Top Stocks Would Be a Brilliant Move
One of the great things about investing in stocks is that there is no need to have millions in the bank to get started. A relatively modest sum such as $1,000 can go a long way if invested shrewdly
With an Acquisition on the Way, Is Biogen Stock a Buy?
Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news. After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it
With an Acquisition on the Way, Is Biogen Stock a Buy?
Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news. After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it
With an Acquisition on the Way, Is Biogen Stock a Buy?
Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news. After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it
STAAR Surgical Teams Up With Tennessee Titans Quarterback Will Levis On Life Changing Vision Correction Procedure, EVO ICL
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced its partnership with Will Levis, quarterback for the
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Is Vertex Pharmaceuticals Stock a Buy Now?
As one of the hottest and most-watched companies in the biopharmaceutical sector, Vertex Pharmaceuticals (NASDAQ: VRTX) has a unique mix of stability and growth potential that's attractive to a
Is Vertex Pharmaceuticals Stock a Buy Now?
As one of the hottest and most-watched companies in the biopharmaceutical sector, Vertex Pharmaceuticals (NASDAQ: VRTX) has a unique mix of stability and growth potential that's attractive to a
Is Vertex Pharmaceuticals Stock a Buy Now?
As one of the hottest and most-watched companies in the biopharmaceutical sector, Vertex Pharmaceuticals (NASDAQ: VRTX) has a unique mix of stability and growth potential that's attractive to a
Is This MedTech Giant a Buy for Dividend Investors?
Buying industry-leading companies in industries with growth potential tends to produce delightful results for dividend investors. This is because such businesses can generate revenue and earnings
EQS-News: STRATEC POSTS FINAL RESULTS FOR FIRST HALF OF 2023
Why Novocure Was a Healthy Stock Today
Cancer-focused biotech Novocure (NASDAQ: NVCR) was the focus of an analyst upgrade on Tuesday, and the stock benefited from the move. In late-session trading that day, it was up by more than 3.3% in
Zoetis (ZTS) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q2 2023 Earnings CallAug 08, 2023, 8:30 a.m. ET
Operator
Source Fool.com
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday
Shares of Enanta Pharmaceuticals (NASDAQ: ENTA) were down more than 9% as of 11:45 a.m. on Tuesday after the clinical-stage biotech released fiscal third-quarter earnings on Tuesday. The stock is
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today
Weight loss drugmakers are having an exceptionally strong trading session today. As of 10:32 a.m. ET Tuesday morning, Eli Lilly (NYSE: LLY) was up by a noteworthy 16.7%, Novo Nordisk (NYSE: NVO) was
Is Sage Therapeutics a Contrarian Buy?
Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that
Is Sage Therapeutics a Contrarian Buy?
Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that
Is Sage Therapeutics a Contrarian Buy?
Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that